Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 11/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.38 |
| ▸ | FNTA | P49354 | 3/20 | 0.37 |
| ▸ | FNTB | P49356 | 3/20 | 0.37 |
| ▸ | PDE5A | O76074 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4917879 | 0.93 | AR (0.49) | ARMAPTLMNATSHRSMN1; SMN2 | |
| SCHEMBL4919103 | 0.90 | AR (0.56) | ARMAPTLMNATSHRSMN1; SMN2 | |
| SCHEMBL4921240 | 0.87 | AR (0.64) | ARLMNATDP1HSP90AA1HSP90B1 | |
| SCHEMBL4913951 | 0.83 | AR (0.50) | ARMAPTLMNATSHRSMN1; SMN2 | |
| SCHEMBL4911697 | 0.83 | AR (0.67) | ARMAPTLMNATSHRSMN1; SMN2 | |
| SCHEMBL4920793 | 0.83 | AR (0.45) | ARMAPTLMNATSHRSMN1; SMN2 | |
| SCHEMBL4915856 | 0.81 | AR (0.53) | ARMAPTLMNATSHRSMN1; SMN2 | |
| SCHEMBL4919894 | 0.80 | AR (0.58) | ARMAPTLMNATSHRSMN1; SMN2 | |
| SCHEMBL4915699 | 0.80 | AR (0.58) | ARMAPTLMNATSHRSMN1; SMN2 | |
| SCHEMBL4914113 | 0.80 | AR (0.66) | ARTDP1FNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176906-A1 | Substituted Pyrrole Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176906-A1 | Substituted Pyrrole Derivative | AR, NR5A1, MC2R | AR 1/4885MAPT 4670/4885LMNA 4414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.